MAP Pharmaceuticals Reports Positive Phase 2 Results For Its Inhaled Migraine Drug Candidate

Fri, 02 Mar 2007 02:00 PM EST

... MAP Pharmaceuticals, Inc. announced today that its Tempo(TM) Migraine drug candidate met its primary endpoints in a Phase 2 clinical program consisting of two separate trials. The candidate is a proprietary orally inhaled formulation of dihydroergotamine (DHE) for the treatment of acute migraine. [click link for full article] ...